Stockholm-based Neko Health, the body-scanning preventative healthcare tech firm co-founded by CEO Hjalmar Nilsonne and Spotify founder Daniel Ek, has announced the completion of its $700 million Series C funding round.
The round was led by Lightspeed Venture Partners and co-led by O.G. Venture Partners, with participation from existing investors Atomico, General Catalyst and Lakestar, alongside new backers including Liberty City Ventures, Positive Sum, and BDT & MSD.
As part of the round, David Ofer of O.G. Venture Partners will join the Neko Health board of directors, subject to regulatory approval. The fundraise follows a $260 million Series B in January 2025.
Neko Health’s first US clinics will open in New York and other cities this year.
Bejul Somaia, Global Partner, Lightspeed Venture Partners, said: “Over the past eighteen months, Neko Health has demonstrated remarkable innovation and growth, attacking one of the largest markets in the world with breakthrough technology, proven consumer demand, and a clear path to global scale.
“We believe this is one of the most important healthcare companies of our generation, and we’re proud to deepen our partnership as they continue to reimagine prevention.”
Eyal Ofer of O.G. Venture Partners said: “We’ve known Hjalmar, Daniel and the founding team at Neko Health for years and have deep respect for their vision to redefine health for more than just the privileged few, on a global scale. They execute at a level few can match.”
The funding round also saw participation from Ari Emanuel, Claudia Schiffer and Sir Matthew Vaughn, Danny Meyer, Jimmy Iovine, Maria Sharapova, Mark Zuckerberg and Priscilla Chan, Thierry Henry, Tim Ferriss and will.i.am, joining existing investors including Alexis Ohanian from Seven Seven Six, Alex Tew and Michael Acton-Smith from Calm, Gary Vaynerchuk, Jessie Inchauspé, Katie Haun, Raj Shamani, Steven Bartlett, Zoë Saldaña and Marco Perego-Saldaña.
At the heart of Neko’s offering is the Neko Health Scan. It is a 60-minute, comprehensive, non-invasive, and radiation-free health assessment that captures millions of health data points, priced at £299 in the UK and 2,750 SEK in Sweden.
Using proprietary sensors alongside blood analysis, the scan assesses skin health, including moles and marks, biomarkers to identify pre-diabetes risk, as well as blood abnormalities, and risk factors linked to metabolic syndrome, stroke, and heart attack.
Results are delivered on-site within minutes and discussed during an in-person consultation with a medical professional, providing members with personalized and actionable health findings.
Hjalmar Nilsonne, Neko Health Co-Founder and CEO, said: “This funding is a strong vote of confidence in what we set out to do when we opened our first clinic three years ago: a completely new healthcare experience designed to keep people healthy, catch problems early and help prevent disease before it even starts.
“With this round, we’re taking that mission to the US for the first time, while continuing to invest in the research and technology that make prevention possible at scale. The clearest proof is in our members: the vast majority of our members return after their first scan, and when they do, their health markers move in the right direction.”